Scholarlink

Purpose <p>Glioblastoma (GBM) invariably develops resistance to temozolomide (TMZ), necessitating novel therapeutic strategies. This study demonstrates that inhibiting exosome secretion with GW4869 remodels the glucose metabolic phenotype to suppress malignant behavior and reverse TMZ resistance in GBM.</p> Methods <p>TMZ-resistant glioblastoma cells (U87TR) were established via concentration-gradient induction. Metabolic profiling was performed using LC-MS. GW4869’s effects were assessed via functional assays (invasion, migration, colony formation), exosome add-back experiments, and ¹⁸F-FDG PET/CT in xenografts. Glycolytic proteins (GLUT-1/HK2/PKM2) were analyzed by immunofluorescence/western blot.</p> Results <p>U87TR cells exhibited glycolytic hyperactivation. GW4869 (10 µM) suppressed invasion, migration and colony formation without cytotoxicity. It reversed TMZ resistance by downregulating GLUT-1/HK2/PKM2 and inhibiting glycolysis. Exosomes conferred resistance via metabolic remodeling—blocked by glycolytic inhibitor 2-DG. In vivo, GW4869 reduced tumor ¹⁸F-FDG uptake by 28.0% (<i>P</i> &lt; 0.01), and this reduction strongly correlated with in vitro IC₅₀ reduction.</p> Conclusion <p>GW4869 overcomes TMZ resistance by inhibiting exosome-mediated glycolytic reprogramming. ¹⁸F-FDG PET provides a clinically applicable quantitative tool for monitoring resistance reversal.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

18F-FDG PET imaging reveals GW4869’s suppression of glioblastoma malignant progression and reversal of TMZ chemoresistance via glucose metabolic phenotype remodeling

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月21日

查看全文
  • Fengfeng Han,
  • Yinghui Xu,
  • Chen Qian,
  • Baosheng Meng,
  • Xiaofei Mo,
  • Yuyun Chen,
  • Xinrui Zhu,
  • Chen He,
  • Mingge Zhou,
  • Zhou Zhang

摘要

Purpose

Glioblastoma (GBM) invariably develops resistance to temozolomide (TMZ), necessitating novel therapeutic strategies. This study demonstrates that inhibiting exosome secretion with GW4869 remodels the glucose metabolic phenotype to suppress malignant behavior and reverse TMZ resistance in GBM.

Methods

TMZ-resistant glioblastoma cells (U87TR) were established via concentration-gradient induction. Metabolic profiling was performed using LC-MS. GW4869’s effects were assessed via functional assays (invasion, migration, colony formation), exosome add-back experiments, and ¹⁸F-FDG PET/CT in xenografts. Glycolytic proteins (GLUT-1/HK2/PKM2) were analyzed by immunofluorescence/western blot.

Results

U87TR cells exhibited glycolytic hyperactivation. GW4869 (10 µM) suppressed invasion, migration and colony formation without cytotoxicity. It reversed TMZ resistance by downregulating GLUT-1/HK2/PKM2 and inhibiting glycolysis. Exosomes conferred resistance via metabolic remodeling—blocked by glycolytic inhibitor 2-DG. In vivo, GW4869 reduced tumor ¹⁸F-FDG uptake by 28.0% (P < 0.01), and this reduction strongly correlated with in vitro IC₅₀ reduction.

Conclusion

GW4869 overcomes TMZ resistance by inhibiting exosome-mediated glycolytic reprogramming. ¹⁸F-FDG PET provides a clinically applicable quantitative tool for monitoring resistance reversal.